Citigroup
HZNP

Citigroup’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Citigroup’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-125,000
Closed -$14.2M – 6102
2022
Q4 		$14.2M Buy
+125,000
New +$10.4M 0.01% 957
2021
Q4 		– Sell
-53,800
Closed -$5.89M – 6274
2021
Q3 		$5.89M Buy
+53,800
New +$5.59M ﹤0.01% 1702
2021
Q2 		– Sell
-43,200
Closed -$3.98M – 6630
2021
Q1 		$3.98M Buy
43,200
+33,500
+345% +$2.83M ﹤0.01% 1958
2020
Q4 		$710K Sell
9,700
-46,800
-83% -$3.48M ﹤0.01% 3881
2020
Q3 		$4.39M Buy
56,500
+12,600
+29% +$867K ﹤0.01% 1976
2020
Q2 		$2.44M Buy
43,900
+29,200
+199% +$1.25M ﹤0.01% 2586
2020
Q1 		$435K Sell
14,700
-6,900
-32% -$233K ﹤0.01% 4000
2019
Q4 		$782K Buy
21,600
+9,600
+80% +$294K ﹤0.01% 4015
2019
Q3 		$327K Buy
12,000
+1,600
+15% +$41.4K ﹤0.01% 4740
2019
Q2 		$250K Hold
10,400
– – ﹤0.01% 5072
2019
Q1 		$275K Sell
10,400
-11,000
-51% -$261K ﹤0.01% 4788
2018
Q4 		$418K Sell
21,400
-46,200
-68% -$906K ﹤0.01% 4333
2018
Q3 		$1.32M Buy
67,600
+46,800
+225% +$890K ﹤0.01% 3172
2018
Q2 		$344K Sell
20,800
-25,900
-55% -$395K ﹤0.01% 4485
2018
Q1 		$663K Buy
46,700
+6,000
+15% +$88.6K ﹤0.01% 3695
2017
Q4 		$594K Buy
40,700
+6,600
+19% +$92.7K ﹤0.01% 3929
2017
Q3 		$432K Buy
34,100
+3,400
+11% +$43.2K ﹤0.01% 4265
2017
Q2 		$364K Buy
30,700
+9,300
+43% +$116K ﹤0.01% 4293
2017
Q1 		$316K Sell
21,400
-51,200
-71% -$829K ﹤0.01% 4258
2016
Q4 		$1.18M Sell
72,600
-11,100
-13% -$201K ﹤0.01% 3510
2016
Q3 		$1.52M Buy
83,700
+58,700
+235% +$1.15M ﹤0.01% 2771
2016
Q2 		$412K Sell
25,000
-2,200
-8% -$35.6K ﹤0.01% 3858
2016
Q1 		$451K Sell
27,200
-45,700
-63% -$800K ﹤0.01% 4240
2015
Q4 		$1.58M Buy
72,900
+16,300
+29% +$317K ﹤0.01% 2674
2015
Q3 		$1.12M Buy
56,600
+42,500
+301% +$1.34M ﹤0.01% 2972
2015
Q2 		$490K Buy
14,100
+11,100
+370% +$339K ﹤0.01% 3723
2015
Q1 		$78K Buy
+3,000
New +$55K ﹤0.01% 5220

Other funds holding HZNP

IA
IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $8.74B AUM 14.62% 1-Year Est. Return
VWA
Valued Wealth Advisors Holladay, Utah $247M AUM 21.93% 1-Year Est. Return
FSWA
Financial Synergies Wealth Advisors Houston, Texas $1.18B AUM 31.41% 1-Year Est. Return
BCMLT
Beacon Capital Management LLC (Tennessee) Franklin, Tennessee $567M AUM 16.01% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Citigroup's HZNP Position: Q4 2023 in Review

Citigroup sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2023, closing a stake of 350,151 shares — an estimated $40.5M sold.

Citigroup first reported a position in HZNP in Q2 2013 and held it in 42 quarters. The position peaked at $42.4M in Q3 2021. 6 funds tracked by Wall St. Rank hold HZNP as of Q4 2023.

  • Citigroup reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2023 after selling out during the quarter.
  • Citigroup sold 350,151 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2023, an estimated $40.5M.
  • Citigroup first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q2 2013 and held it in 42 quarters.
  • Citigroup's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $42.4M in Q3 2021.
  • 6 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2023.

Based on Citigroup's 13F filing for Q4 2023, filed 9 Feb 2024.